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High throughput screening for inhibitors of the HECT
ubiquitin E3 ligase ITCH identifies antidepressant
drugs as regulators of autophagy
M Rossi1,2, B Rotblat1, K Ansell3, I Amelio1, M Caraglia4, G Misso4, F Bernassola5, CN Cavasotto2, RA Knight1, A Ciechanover*,6
and G Melino*,1,5
Inhibition of distinct ubiquitin E3 ligases might represent a powerful therapeutic tool. ITCH is a HECT domain-containing E3
ligase that promotes the ubiquitylation and degradation of several proteins, including p73, p63, c-Jun, JunB, Notch and c-FLIP,
thus affecting cell fate. Accordingly, ITCH depletion potentiates the effect of chemotherapeutic drugs, revealing ITCH as a
potential pharmacological target in cancer therapy. Using high throughput screening of ITCH auto-ubiquitylation, we identified
several putative ITCH inhibitors, one of which is clomipramine—a clinically useful antidepressant drug. Previously, we have
shown that clomipramine inhibits autophagy by blocking autophagolysosomal fluxes and thus could potentiate chemotherapy
in vitro. Here, we found that clomipramine specifically blocks ITCH auto-ubiquitylation, as well as p73 ubiquitylation.
By screening structural homologs of clomipramine, we identified several ITCH inhibitors and putative molecular moieties that are
essential for ITCH inhibition. Treating a panel of breast, prostate and bladder cancer cell lines with clomipramine, or its
homologs, we found that they reduce cancer cell growth, and synergize with gemcitabine or mitomycin in killing cancer cells by
blocking autophagy. We also discuss a potential mechanism of inhibition. Together, our study (i) demonstrates the feasibility of
using high throughput screening to identify E3 ligase inhibitors and (ii) provides insight into how clomipramine and its structural
homologs might interfere with ITCH and other HECT E3 ligase catalytic activity in (iii) potentiating chemotherapy by regulating
autophagic fluxes. These results may have direct clinical applications.
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Ubiquitylation regulates cell physiology and pathology by
complex posttranslational protein modifications.1–3 Protein
ubiquitylation consists of three discrete steps carried out by
ubiquitin (Ub)-activating enzymes (E1), Ub-conjugating
enzymes (E2) and Ub ligases (E3).4 E3 ligases are classified
into three subfamilies based on the sequence homology of
their E2 binding domains: RING (Really Interesting New
Gene), HECT (Homologous to E6AP Carboxyl Terminus) and
U-boxes.5 The HECT E3 ligases are unique among the E3s,
because they possess intrinsic catalytic activity.6 The basic
structural motif of the HECT E3 ligases is a large C-terminal
module of circa 350 residues. The reaction requires several
steps, (i) binding to E2, (ii) Ub loading, forming a Ub–thioester
intermediate with the catalytic cysteine located at the
C-terminus of the HECT domain, and (iii) Ub transfer to the
substrate protein with a conformational transition and rotation
of the catalytic domain onto an hinge region.7
The HECT E3s gain their substrate specificity by selective
protein–protein interaction domains, accounting for their
classification into three subfamilies: HERC E3s containing
RCC1-like domains (RLDs), C2-WW-HECT E3s possessing
WW domains, and SI(ngle)-HECT E3s lacking either RLDs or
WW domains.6 The C2-WW-HECT E3s are the best-
characterized subgroup of HECT ligases. They contain an
N-terminal protein kinase C (PKC)-related C2 domain and two
to four tryptophan-containing WW domains that regulate
E3-substrate interaction.6 ITCH belongs to this sub-family.8
ITCH was originally identified because radiation-induced
disruption of the Itch gene induced a lethal autoimmune
inflammatory condition.9 ITCH was later found to be crucial in
the control of the proteosomal degradation of several
important substrates involved in the regulation of the
programmed cell death pathway and/or the inflammatory
response, including the p53 family members p73 and p63,10–17
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the cellular FLICE-inhibitory protein,18 the small redox proteins
Thioredoxin,19 the membrane-targeted death ligand tBid,20 the
tumor suppressor RASSF5/NORE1 RASSF5,21 the large
tumor suppressor 1 LATS1,22 the lysosomal-associated
protein multispanning transmembrane 5 LAPTM5,23 the
epithelial kinase receptor ErbB4,24 members of the activator
protein 1 c-Jun and JunB,25 the phospholipase C-g1 and
protein kinase y PLC-g1/PKC-y,26,27 the Ub-editing enzyme
A20,28 Notch1,29 proteins involved in the TGFbR signaling
Smad and TIEG130,31 and the chemokine receptor 4CXCR4.32
Since ITCH is relevant in regulating immunological
responses as well as cancer progression,33–36 and because
HECT E3s are the most druggable of the entire family, we
decided to investigate the possibility of identifying ITCH
inhibitors using a high throughput screen (HTS). To identify
such inhibitors we developed an ELISA-based HTS using
purified recombinant proteins and auto-ubiquitylation as
readout for ITCH activity. Here, we characterized one of the
inhibitor compounds, clomipramine, able to block p73
ubiquitylation by binding to ITCH in an irreversible manner
and inhibiting its charging with Ub. We found that, in addition
to their ITCH inhibitory activity, clomipramine and its structural
homolog norclomipramine, induce autophagosome accumu-
lation and synergize with chemotherapeutics in killing cancer
cell lines in vitro.
Results
HTS assay to detect ITCH inhibitors. To identify low
molecular weight compounds that are potential ITCH
inhibitors, we established an ELISA-based HTS assay. To
reduce the complexity of the assay we decided to use ITCH
auto-ubiquitylation as the readout for ITCH activity
(Figure 1a).8,37 Our results demonstrate that the signal
detected in our experimental setting was strictly dependent
on ITCH Ub ligase activity, as a parallel experiment using
mutant enzymatically inactive ITCH (E3m) did not generate
any significant signal (Figure 1b). We then measured the
dynamic range of our in vitro ubiquitylation assay using
increasing concentrations of immobilized wild type ITCH and
observed a dose-dependent change in signal intensity with
an EC50 ofB5ng per well (Figure 1c). As predicted, mutant
ITCH tested in parallel gave only a baseline signal at all
concentrations tested, further confirming that the signal
detected in our experimental conditions was dependent on
the Ub ligase activity of ITCH.
HTS identification of ITCH inhibitors. Using the assay
described in the previous paragraph we screened 1040
compounds from the NINDS library and B20 000 diverse
compounds from various commercial suppliers at a final
concentration of 10 mM each. The automated assay was
robust according to an average recorded Z0 of 0.7 (range
0.5–0.8). The normalized single shot screening data for the
NINDS set is shown in Figure 1d. Potential ITCH inhibitors
(‘hits’) were identified from test wells yielding normalized
residual activity results o3 S.D. from the mean of the high
controls. Hits were further ranked more stringently according
to 70 and 50% residual activity thresholds. The overall hit
rate at the 50% cutoff was low (0.23%), suggesting that the
ITCH inhibition with small molecules is relatively rare. Of 46
compounds showing o50% residual activity that were
initially identified as hits, 20 were confirmed at single point
and 6 of these showed dose-dependent inhibition of ITCH
(Figure 1e and Table 1).
Validation of putative ITCH inhibitors. To validate the
results obtained from the HTS we used a more direct assay
to visualize the formation of Ub conjugates. For this purpose,
recombinant GST-ITCH was incubated with E1 and E2 in the
presence of candidate inhibitors or vehicle and auto-
ubiquitylation was determined by Western blotting using
anti-GST antibodies (Figure 2a). Interestingly, using this
assay we found that only clomipramine (compound 8,
MRT0003986) significantly inhibited ITCH auto-ubiquityla-
tion, as demonstrated by the disappearance of high
molecular weight ITCH species present in the positive control
(Figure 2a; lane 8 versus 2).
In accordance with the auto-ubiquitylation experiment, we
found that clomipramine significantly inhibited ITCH-depen-
dent ubiquitylation of p73, a well characterized ITCH
substrate, as demonstrated by the disappearance of high
molecular weight p73 species present in the positive control
(Figure 2b; lane 8 versus 2). As expected, incubation of p73
with the ligase dead ITCH mutant did not produce any
detectable high molecular weight p73 Ub conjugates
(Figure 2b; lane 1). Inhibition of ITCH-dependent p73
ubiquitylation by clomipramine was dose-dependent achiev-
ing complete inhibition at 0.8 mM (Figure 2c; lane 6). These
results are consistent with the findings that clomipramine
inhibited ITCH auto-ubiquitylation activity and support the
conclusion that it is an ITCH E3 ligase inhibitor.
To evaluate whether clomipramine is a general inhibitor of
E3 ligases or specific for ITCH, we tested whether clomipra-
mine can inhibit other E3 ligases. To answer this question we
assessed the effect of clomipramine on the auto-ubiquitylation
of Ring1B, a RING domain E3 ligase, the ubiquitylation of
Ring1B by the HECT E3 ligase E6AP38 and the ubiquitylation
of Dronc by the RING E3 ligase DIAP39 (Figure 2d). The
specificity of the ubiquitylation reaction was confirmed by
excluding the E2 in the control lanes (Figure 2d; lanes 1, 4, 7
and 10). As expected, clomipramine inhibited p73 ubiquityla-
tion by ITCH (Figure 2d; lane 2 versus 3). Interestingly, the
RING E3 ligases Ring1B and DIAP were resistant to
clomipramine inhibition and retained their ubiquitylation
activity (Figure 2d; lanes 5 versus 6 and 11 versus 12), while
the HECT E3 ligase E6AP was blocked by clomipramine
(Figure 2d; lanes 8 versus 9). Together these results suggest
that clomipramine is an efficient inhibitor of ITCH with some
general degree of specificity for HECT E3 ligases; it does not
inhibit any RING E3 ligase tested so far. Moreover as E6AP
and ITCH show no significant sequence homology except in
their HECT domain it is reasonable to speculate that
clomipramine primarily acts directly on the catalytic domain
of these two enzymes.
Clomipramine inhibits Ub transthiolation of ITCH.
Because ubiquitylation requires the concerted action of E1,
E2 and E3, we asked whether the clomipramine inhibitory
effect in the Ub conjugation assays was a result of direct
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inhibition of ITCH E3 ligase activity or an impairment of E1
and/or E2 activity. To answer this question we incubated
recombinant E2 (UbcH7) with E1 in the presence or absence
of clomipramine and analyzed the E2 Ub transthiolation by
Coomassie staining (Figure 3a). Our results show that
clomipramine does not inhibit UbcH7 Ub transthiolation, as
demonstrated by the appearance of a shift in the UbcH7
band comparable with the samples incubated with vehicle
solution (Figure 3a; lanes 2 versus 5). As a control of E2 Ub
transthiolation inhibition we used b-mercaptoethanol that
efficiently prevented thioester bond formation between Ub
and UbcH7 (Figure 3b; lanes 3, 6). In addition, we also
repeated similar experiments using only E1 and obtained
comparable results (data not shown), indicating that both E1
and E2 were completely resistant to the inhibitory effect of
clomipramine. These results are in line with the finding that
clomipramine does not block the activity of RING1B or DIAP1
(Figure 2d). We then tested whether clomipramine was
acting on ITCH Ub transthiolation or on the ITCH Ub chain
elongation activity. To this end, we performed similar
experiments as described in Figure 3a using recombinant
GST-ITCH and Western blot analysis using anti-GST
Figure 1 High throughput screening (HTS) for ITCH inhibitors. (a) Schematic representation of the layout of the ELISA assay used for the HTS. Recombinant GST-ITCH
or ubiquitin ligase dead mutant GST-ITCH C830A were immobilized to glutathione-coated ELISA plates and incubated with either complete ubiquitylation reaction mixtures
containing E1, E2 (UbcH7) and FLAG-ubiquitin or partial mixtures as indicated in (b). Reactions were performed for 1 h at RT and stopped by washing with PBST before
development with HRP-conjugated anti-FLAG antibody for 1 h at RT. After final washes, the wells were incubated with TMB substrate for 15 min at RT, and then stopped with
acid and OD450 nm measurements were made with a plate reader. (b) Different combinations of the ubiquitin reaction components were used to evaluate the specificity of the
ubiquitylation reaction (E3, GST-ITCH; E3m, E3 ligase dead mutant GST-ITCH C830A). (c) Complete reactions were performed as in (b) using a range of E3 or E3m
concentrations immobilized to the ELISA plate as shown. (d) Normalized screening data for 1040 compounds from the NINDS library. Immobilized GST-ITCH was incubated
with test compounds (10 mM) and E1/E2/Ub mix. After incubation at RT for 2 h, plates were developed with HRP-conjugated anti-FLAG and TMB substrate as above.
Percentage residual activity (%RA) was calculated using the formula %RA¼ (OD450 sample—mean OD450 low controls)/(mean high controls—mean OD450 low
controls) 100. Z prime values were calculated with a threshold of40.5 set for acceptable data. 70 and 50% thresholds are indicated with lines. (e) Confirmation of six
positive hits using does response and the ELISA system as in Figure 1c
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antibodies (Figure 3b). In contrast to the results obtained in
the E2 Ub transthiolation experiments, we observed a strong
inhibitory effect of clomipramine on ITCH Ub transthiolation
(Figure 3b; lane 5).
Next we asked whether the inhibitory effect of clomipramine
on ITCH catalytic activity is reversible or irreversible. To
answer this question we incubated GST-ITCH with clomipra-
mine or vehicle control (DMSO), subjected it to dialysis to
dilute low affinity and unbound clomipramine and subse-
quently incubated it with E1 and E2 in Ub assay buffer.
Auto-ubiquitylation activity was clearly evident in the DMSO
pretreated ITCH samples but totally absent in the clomipra-
mine pretreated samples (Figure 3c; lanes 1 versus 4).
As an internal reaction control we added untreated GST-ITCH
to the dialyzed samples and found adequate auto-ubiquityla-
tion activity, even in the samples that were preincubated
with clomipramine before the dialysis (Figure 3c; lane 5 and 6).
In agreement with these results, we observed that clomipra-
mine pretreated and dialyzed ITCH failed to promote the
formation of p73 Ub conjugate species (Figure 3d; lanes 4
versus 8).
Together these data suggest that clomipramine is a specific
ITCH inhibitor that interferes with the HECT Ub transthiolation
activity of this enzyme in an irreversible manner.
Activity of structural analogs of clomipramine. To obtain
a qualitative insight into the putative molecular moieties that
are essential for ITCH inhibition by clomipramine we tested
17 clomipramine structural analogs for their ability to block
ITCH Ub ligase activity. To this end, similar experiments as
described in Figure 2a were performed using increasing
doses of the different compounds tested (Figure 4). The
structures of the analogs and minimum tested concentrations
achieving ITCH auto-ubiquitylation inhibition are shown in
Table 2. The results obtained show that all the compounds
that were found to inhibit ITCH activity at a concentration
close to 300 mM contained a Cl group at the aromatic moiety.
In addition, we found that the extent of methylation of the final
amine group on the side chain decreases the inhibitory effect
of the compounds (Figure 4f). Interestingly, norclomipramine,
the active metabolite of clomipramine, was found to be the
most efficient ITCH inhibitor tested.
Table 1 Validation of compounds identified in the high throughput screen
Abbreviations: ND, non dialyzed; NINDS, National Institute of Neurological Disorders and Stroke.
The indicated compounds were tested in single point at 10mMwith repeats as indicated and in dose response on at least three independent occasions in the ELISA assay.
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Clomipramine and Norclomipramine inhibit autophagy
and synergize with chemotherapeutics in killing cancer
cells. Autophagy is a major cellular process involved in
detoxification, and autophagy inhibitors have been show to
promote the activity of anti-cancer drugs40 and are therefore
under investigation as potential therapeutic agents in treating
cancer.41 Clomipramine has been shown to synergize with
doxorubicin in killing HeLa and MEF cells by blocking
autophagic flux.40 Therefore, we tested whether clomipramine
has activity on other cancer cell lines, can synergize with other
chemotherapeutics and whether these activities are present in
clomipramine’s structural analog norclomipramine.
First, we measured autophagosome accumulation in RT112
or HT-1376 cells treated with the ITCH inhibitors or chemo-
therapeutics separately or in combination using monodansyl-
cadaverine fluorescence as readout for autophagosomes.42 As
expected, clomipramine or norclomipramine, alone increased
autophagosome accumulation (Supplementary Figure S1a–d).
In addition, while gemcitabine or mitomycin alone increased
autophagosome accumulation (Supplementary Figure S1a–d),
the combination of an ITCH inhibitor with these chemother-
apeutic agents resulted in further increased autophagosome
accumulation as compared with the individual compounds
alone (Supplementary Figure S1a–d). Together these results
support the premise that the two putative ITCH inhibitors block
autophagic flux in RT112 and HT-1376 cells and are in line with
our preliminary previously published data.
Next we asked whether the identified putative ITCH
inhibitors could synergize with chemotherapeutics. To this
end we treated bladder cancer cells HT-1376 with clomipra-
mine alone or in combination with the chemotherapeutic agent
gemcitabine and measured cell growth and induction of cell
death. Indeed, the combination of clomipramine and gemci-
tabine was shown to be synergistic (Figures 5a and c and
Supplementary Figure S2). Similar results were obtained
using RT112 cells treated with norclomipramine alone or in
combination with mitomycin (Figures 5b and d and
Supplementary Figure S3). The data was analyzed using
CalcuSyn software (Biosoft, Cambridge, UK)43 to determine
synergism between the compounds (Supplementary Table 1).
To test whether ITCH inhibitors can inhibit cell growth, we
challenged a panel of breast, prostate and bladder cancer cell
lines (Supplementary Figures 4–6) with different doses of
the clomipramine and norclomipramine, for 48 or 72h
(Supplementary Figures 4–6) andmeasured cell growth using
a MTT assay. Both clomipramine and norclomipramine
exhibited IC50 values at low micromolar concentrations for
all of the tested cell lines (Supplementary Table 2–4).
Figure 2 Validation of the identified putative ITCH inhibitors. (a) GST-ITCH (ITCH WT) or E3 ligase dead mutant GST-ITCH (ITCH MUT) were incubated in ubiquitylation
assay buffer with DMSO or the putative ITCH inhibitors (1 mM). The reaction products were subjected to Western blot analysis. (b) 35S labeled p73 was reacted with ITCH or
E3 ligase dead mutant ITCH in the ubiquitylation assay buffer in the presence of DMSO or putative ITCH inhibitors (1 mM) as indicated. The reaction was subjected to SDS-
PAGE and resolved by autoradiogram. (c) p73 ubiquitylation assay performed as in (b) in the presence of the indicated concentrations of clomipramine (compound 8). As
control for ubiquitylation reaction E3 ligase dead mutant ITCH (lane 1) substituted the WT ITCH. (d) The indicated substrates labeled with 35S were incubated with the indicated
E3 ligases in the presence or absence of clomipramine as indicated. The reaction was resolved by SDS-PAGE and radiogram. Control reactions were performed without the
E2 as indicated
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Because in vitro clomipramine and norclomipramine inhibited
ITCH at high micromolar concentrations (300 mM;
Supplementary Table 1) but inhibited cancer cell growth at a
low micromolar concentrations (6–30 mM; Supplementary
Table 2–4) these data suggest that the putative ITCH
inhibitors block cell growth through an ITCH independent
mechanism and support the conclusion that clomipramine
blocks cell growth by blocking autophagic flux.
Discussion
HTS reveals clomipramine as an ITCH inhibitor
regulating autophagy. We undertook the challenge of
performing a HTS for inhibitors of E3 ligases and success-
fully identified small molecule ITCH inhibitors, providing a
proof of concept and a screening strategy for identification of
HECT E3 ligase inhibitors. This provides a proof of concept
for a screening strategy for the identification of other HECT
E3 ligase inhibitors in the future. Our first unexpected result
was the identification of the antidepressant drug clomipra-
mine as an E3 inhibitor. Although E3s were not known as a
chemical entity at the time when the molecular mechanism of
these antidepressant drugs was identified, this suggests the
possibility either of a novel mechanism of action, or that a
HECT-containing E3 acts on that pathway, for example,
regulating the degradation of the serotonin receptor or its
recycling mechanism. Alternatively, the effect of clomipra-
mine on HECT E3s could be an off-target effect, although
very powerful. A second surprise was the discrepancy in
concentration for the biochemical and the cellular effects of
clomipramine. On this point, we have to stress that the
biochemical machinery of proteolysis is extremely compli-
cated, unlike the kinases or phosphatases, and therefore the
concentration for its biochemical visualization could differ
Figure 3 Clomipramine mechanism of inhibition. (a) HIS-UbcH7 was incubated with E1 either with DMSO or clomipramine in the presence or absence of
b-mercaptoethanol as indicated along with ubiquitylation assay buffer. Reaction was subjected to SDS-PAGE and the gel was stained with Coomassie blue. (b) GST-ITCH or
E3 ligase dead mutant GST-ITCH were incubated either with DMSO or clomipramine in the presence or absence of b-mercaptoethanol and ubiquitylation reaction buffer. The
reaction was resolved by Western blot using anti-GST antibodies. (c) GST-ITCH was incubated with DMSO or clomipramine as indicated and then dialyzed. The dialyzed GST-
ITCH was subjected to ubiquitylation reaction. The reaction was resoled using Western blot and anti-GST antibodies. As control, untreated GST-ITCH was added to the
reaction as indicated, N.D., non dialyzed. (d) 35S radio-labeled p73 was reacted with GST-ITCH prepared as in c
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using an in vivo cellular readout. A third unexpected result,
already partially published by our group40 was the ability of
clomipramine to inhibit autophagy. Is this related to the
molecular mechanism of action as an antidepressant? do all
antidepressant drugs, including those chemically unrelated to
clomipramine, share this autophagic regulation? clearly this
is an interesting point for future investigations. Here, we
expanded our previous observation40 showing an evident
synergism for chemotherapy sensitivity. Indeed, we found
that clomipramine shares some structural commonalities with
chloroquine, a well-established inhibitor of autophagic flux
and that clomipramine and its structural homolog blocked
autophagic flux and synergized with chemotherapeutics
in inhibiting the growth and viability of a panel of different
cancer cells. This could form a prelude to an ad hoc
clinical trial.
Is the effect of clomipramine dependent of p73? as
discussed in the Introduction, ITCH, like any other E3, has a
significant number of substrates, and discriminating among
different E3 targets may be not easy.44 In turn, p73 can be
ubiquitylated by multiple mechanisms, including Cul4A,45
PIR2,46 antizyme,47 FBX045,48 calpain49 as well as de-
ubiquitylated.50,51 Consequently, the effect of an E3 inhibitor
could depend on the tissue, on the cellular micro-environment
and stimuli, as well as on a distinct combination of multiple E3
substrates present in the cell.
Figure 4 ITCH inhibitions by structural analogs of Clomipramine. (a–e) GST-ITCH was incubated with the indicated concentrations of the indicated structural analogs (A1
to A17) of clomipramine (CL) in ubiquitylation assay buffer. The reactions were resolved by SDS-PAGE and stained with Coomassie. As a control, E2 was excluded from the
reaction. The intensity of nonubiquitylated GST-ITCH band was quantified. (f) Clomipramine molecular moieties important for ITCH inhibition. The presence of a Chloride
(circle in red) on the Benzene ring increases the inhibitory activity of the compounds tested by roughly fivefold or more. The length of the side chain is also critical. Shorter or
longer chains dramatically decrease the inhibitor effect. The Amine number 1 can be substituted by a C¼C double bond, without affecting the inhibition capacity of the
compound. The extent of methylation of amine number 2 affects the inhibitor effect of the compounds tested. A dimethylamine group in this position decreases the inhibitory
potency by a factor of two compared with a monomethylamine
HECT E3 ligase ITCH inhibitors
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Putative mechanism of action of the ITCH inhibitor
clomipramine. Using biochemical assays we found that the
identified compound, namely clomipramine, blocks ITCH Ub
transthiolation in an irreversible manner. Clomipramine
inhibited some other HECT E3 ligases but not RING E3
ligases leading us to hypothesize a putative mechanism of
inhibition.
To further increase our understanding of how clomipramine
derivatives might obstruct ITCH Ub conjugation activity,
modeling studies were performed on the HECT domain of
ITCH. Two potential binding sites were found (see Figure 6a),
and in those full-flexible docking of clomipramine was
performed. The low-energy conformations of the ligand within
each binding site are displayed in Figure 6a. If the ligand were
to bind between the N- and C-lobes, it could prevent the
interaction of Ub with the catalytic C871, and could also
preclude the relative rearrangement of the two lobes for Ub
transfer fromE2, as was theoretically predicted for E6AP7 and
observed in NEDD4L.52 If the ligand were to bind within the
N-lobe, it might also interfere with protein rearrangement
blocking ITCH Ub transthiolation. In both cases, burial of the
Cl atom within the binding site could explain the observed
sensitivity of the binding affinity to Cl deletion (Table 2).
A possible alternative interpretation of the results is that
these compounds interact directly with the thiol group of the
catalytic cysteine (Figure 6b). In this case, a potential
mechanism for the reaction may consist of two steps; the first
is the addition of the nucleophilic sulfur atom, which is rate-
limiting, at the aromatic ring. During this process a new
carbon–sulfur bond is created as a stable intermediate in the
form of a resonance-stabilized carbon anion. The second step
is the elimination of the halogen leaving group which restores
the aromatic system. This possible model is supported by the
findings that clomipramine irreversibly inhibits ITCH and that it
can also inhibit other HECT E3 ligases that have a similar
catalytic cysteine. Interestingly, we observed that the struc-
tures of the ITCH inhibitors are similar to the autophagy
inhibitor chloroquine and present a moiety that resembles the
chloroquine aromatic scaffold (Figure 6c). These include the
heterocyclic structure leading the nitrogen atom, the chloro
substituent as the reactive site for the inhibition reaction and
the alkyl chain bearing a tertiary amine reported to be
important for the activity of autophagy inhibitors that promote
the deacidification of lysosomes and reduce tumor growth
in vivo.53
Discriminating between these possible mechanisms of
action will require further studies.
Conclusion
Growing amount of evidence is accumulating indicating that
deregulation of ITCH and other members of the family of
Nedd4-like E3 ligases that have a crucial role in the onset and
progression of different medical conditions.6,54 Here, we have
(i) successfully performed anHTS for an HECT- containing E3
ligase inhibitors, (ii) identified clomipramine, and its structural
analogs, as inhibitors of ITCH, (iii) shown their ability to
regulate autophagy and chemosensitivity, leading to
Figure 5 Synergistic effect of putative ITCH inhibitors with anti-cancer agents on human bladder cancer cells. Clomipramine/GEM and norclomipramine/MIT synergistic
effect on HT-1376 (a) and RT112 (b) cell growth inhibition, respectively. We have evaluated the growth inhibition induced by different concentrations of clomipramine and GEM
on HT-1376, and of norclomipramine and MIT on RT112 cells. We have performed these experiments with MTT assay and the resulting data were elaborated with the
dedicated software CalcuSyn.43 In the figure it is also shown the isobologram analysis of the effects on growth inhibition of clomipramine/GEM and norclomipramine/MIT
combinations, used at equitoxic (50 : 50) concentrations for all cell lines and also in sequential administration, GEM 24 h after clomipramine for HT-1376 (c), and MIT 24 h after
norclomipramine for RT112 (d). CI, combination index. Each point is the mean of at least four different replicate experiments
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immediate potential clinical application. Clearly, these results
require significant further work to clarify the open points
discussed above. Nonetheless, the results presented here not
only provide valuable information for the development of new
research tools, that may be extremely useful to study ITCH
and other HECT E3 ligases, but also show great translational
potential.
Materials and Methods
Plasmids. Expression vectors were described previously: p73, ITCH, ITCH
mutant, Ub and UBCH7;11 RINGB and E6AP;38 DIAP and Dronc.39
GST fusion proteins. GST fusion proteins were expressed in E. coli BL21
(DE3) and purified on glutathione–sepharose beads (Amersham Biosciences,
Little Chalfont, UK) following standard procedures. Briefly, Glutathione S-transfer-
ase (GST)-tagged ITCH protein and inactivated ITCH mutant (C830A) were
expressed in bacteria. E. coli BL21 CodonPlus(DE3)-RIL cells (Stratagene,
La Jolla, CA, USA) were transformed with either wild type or mutant constructs
prepared in the expression vector pGEX-6P1 (Amersham Biosciences). Saturated
cultures were prepared by inoculation of LB medium containing ampicillin (LB/
amp) with growth overnight at 37 1C. For expression, overnight cultures were
diluted 1/100 in LB/amp at 37 1C until they reached an OD of 0.40. At this point the
temperature was reduced to 15 1C and IPTG (50mM final concentration) was
added to induce expression for 3–4 h with shaking at 250 r.p.m. Cell lystates were
prepared and the GST fusion proteins were purified on glutathione–sepharose
beads (Amersham Biosciences) using standard procedures.
E1 and E2. E1 Ub activating enzyme was expressed in the Baculovirus system
and purified by Ni-NTA chromatography (Qiagen, Manchester, UK) according to
the manufacturer’s instructions. Following expression in E. coli BL21 Codon-
Plus(DE3)-RIL cells (Stratagene), purified E2 was obtained by Ni-NTA affinity
chromatography (Qiagen) according to the manufacturer’s instructions.
FLAG-tagged Ub. Purified recombinant Ub containing an amino terminal
FLAG sequence (DYKDDDDK) was purchased from Sigma Aldrich (Gillingham, UK;
cat. No.U5382).
Anti-FLAG M2 peroxidase conjugate. The anti-FLAG M2 antibody
conjugated to hydrogen peroxidase was purchased from Sigma Aldrich (cat. No. A8592).
Figure 6 HECT domain of ITCH with potential Clomipramine binding sites. (a) Two conformations of the 613–622 loop (missing in the experimental structure 3TUG) are
shown. Low-energy conformations of docked clomipramine in the two sites are displayed in yellow and gray carbons. The catalytic C871 is also displayed as reference. Color
code: C-lobe, red; N-lobe large subdomain, magenta; N-lobe small subdomain, cyan; flexible connecting loops, yellow. (b) The indicated mechanism shows the direct
interaction between the catalytic sulfidrilic group of ITCH HECT domain and the aromatic ring of the ITCH inhibitors. The resonance-stabilized adduct favors the elimination of
the halogen group with the formation of a new covalent bond. (c) Comparison between the structures of chloroquine and clomipramine showing the similarity of their scaffolds:
highlighted with stars and boxes are the Cl atoms and the alkyl chains, respectively
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TMB ELISA substrate. The peroxidase substrate 3,30,5,50-tetramethylben-
zidine (TMB), was prepared by making a 1% w/v TMB stock (Sigma Aldrich
T-2885) in DMSO and diluting 1/10 into 0.1 M sodium acetate buffer at pH 4.5
containing 0.01% v/v hydrogen peroxide just before use.
Compound libraries. We screened the NINDS library of 1040 bioactive
compounds (ICCB Longwood, Harvard Medical School) and B20 000 diverse
compounds from a range of commercial suppliers (Maybridge (Trevillett, UK),
Interbioscreen (Moscow, Russia), SPECs (Delft, Netherlands), Peakdale
(Chapel-en-le-Frith, UK) and Biofocus (Chesterford Pk, UK)). Library compounds
were solubilized in DMSO at 1 mM in 384-well plates in preparation for screening.
Assay for ITCH auto-ubiquitylation and HTS. ITCH auto-ubiquityla-
tion was assayed by ELISA. GST-ITCH was coated onto clear glutathione-coated
384-well ELISA plates (Pierce, Rockford, IL, USA) at 7 ng/20 ml per well for 1 h at
room temperature (RT). Low control wells (n¼ 24 per plate) were coated with
GST-tagged ITCH E3 ligase dead mutant. E2 (UbcH7) was preincubated with E1
and FLAG-Ub (Sigma) off-plate in a bulk mix (E1/E2/Ub mix). Briefly, a mixture
was prepared containing 51mg/ml UbcH7, 468 ng/ml E1, 1.25 mM ATP in
ubiquitylation buffer (25 mM Tris pH 8.0 containing 100 mM NaCl, 4 mM MgCl2.
and 50mM DTT) and incubated at RT for 45 min. After three washes with PBST
(phosphate-buffered saline pH 7.2 containing 0.1% tween 20), 10 ml of test
compounds pre-diluted to 20 uM in ubiquitylation buffer were added in single point
to assay wells using automated robotics (Beckman Fx, High Wycombe, UK),
followed by 10ml of E1/E2/Ub mix. High control wells (n¼ 24) were incubated with
10ml ubiquitylation buffer containing 2%v/v DMSO followed by 10 ml E1/E2/Ub
mix. The plates were sealed and incubated for 2 h at RT, after which the reactions
were terminated by washing three times with PBST. Bound FLAG peptide
corresponding to incorporation into the E3 was detected by addition of 20 ml anti-
FLAG M2 monoclonal antibody conjugated to horseradish peroxidise (Sigma)
diluted 1/10,000 in PBST and incubated for 1 h at RT, followed by three washes
with PBST and addition of 20ml 0.1% w/v 3,30 0,5,50 0-TMB (Sigma) in 0.1 M sodium
acetate buffer pH 4.5 containing 0.01% v/v hydrogen peroxide for 15 min. The
reactions were stopped by mixing with 5 ml 1 M HCl and reading absorbance at
Table 2 Structural analogs of Clomipramine and their ITCH inhibition activity
The minimum concentration where ITCH auto-ubiquitylation was inhibited was determined using data obtained in Figure 5.
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450 nm using a Safire 2 plate reader (Tecan, Reading, UK). Percentage residual
activity (%RA) was calculated using the formula %RA¼ (OD450 sample—mean
OD450 low controls)/(mean high controls—mean OD450 low controls) 100.
Z prime values were calculated with a threshold of40.5 set for acceptable data.
Hits were identified using a cutoff of o50% residual activity. Dose response
experiments were performed in the same way, except that concentrated
compound stocks were used (10 mM in DMSO) that were serially diluted in
100% DMSO in half log series before addition to the assay plate. The final DMSO
concentration present in the compound test wells was matched in the high and low
controls. Curve fitting was performed using a 4 parameter logistic model
(Graphpad Prism, La Jolla, CA, USA) with baseline constrained to zero.
Ubiquitylation assays. In vitro assays were performed as described
previously.55 In vitro transcription/translation of proteins was performed using the
wheat germ lysate system TNT kit (Promega, Madison, WI, USA), in the presence
of [35S]Met (Amersham Biosciences), according to the manufacturer’s protocol.
The ubiquitylation reaction mixture contained: 1ml of E1 and 1 mg of a E2 (UbcH7
for ITCH and E6AP; Ubch5c for Ring1B; UbcD1 for DIAP), 1 mg of purified E3
enzyme for GST-ITCH, GST-ITCH MUT, E6AP, DIAP1 and 0.3ml for Ring1B,
40 mM Tris–HCl (pH 7.6), 2 mM dithiothreitol, 2.5 mM ATPgS, 2 mM MgCl2 and
5mg of Ub. After incubation for 90 min at 37 1C, the reactions were terminated by
adding 5 Laemmli buffer, resolved by SDS-PAGE, followed by autoradiography.
Western blotting. Proteins were separated on SDS-PAGE and blotted onto
nitrocellulose membranes. Filters were blocked with TBST 5% nonfat dry milk and
incubated with primary antibodies for 2 h at RT. Filters were incubated for 1 h at
RT using the appropriate horseradish peroxidase-conjugated secondary antibody
(rabbit and mouse BioRad). Detection was performed with the enhanced
chemiluminescence Supersignal West Pico (Pierce). Anti-GST is a monoclonal
antibody (Abcam, Cambridge, UK).
Computerized homology structural modeling. For modeling pur-
poses, the unbound structure of HECT domain of ITCH (PDB code 3TUG) was
used. The 613–622 loop, missing in the PDB structure, was built in silico and
subjected to a stochastic global energy optimization using the ICM program
(Molsoft L.L.C., San Diego, CA, USA).56 As the missing loop is assumed to be
flexible, two low-energy conformations of the loop were retained. Clomipramine
was seeded in the two predicted binding sites (Figure 5), and the ligand-receptor
complex structure was optimized using a flexible ligand–flexible receptor docking
protocol,57–59 where low-energy conformations were collected in a conformational
stack. The structure of clomipramine was downloaded from the GPCR Ligand
Library 60 (http://cavasotto-lab.net/Databases/GDD/).
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